Moxibiot (Moxifloxacin)

Moxifloxacin inhibits bacterial DNA gyrase and topoisomerase IV, enzymes required for DNA replication and transcription. This inhibition prevents bacterial DNA from being properly unwound and resealed, leading to lethal double‑strand breaks and bacterial cell death.

The dosage of Moxibiot is determined by the prescribing clinician based on the infection being treated, patient characteristics, and local guidelines. Patients should follow the exact regimen provided by their healthcare professional.

The safety of moxifloxacin during pregnancy or lactation has not been definitively established. Clinicians should weigh potential benefits against possible risks and consider alternative therapies when treating pregnant or nursing individuals.

To order Moxibiot, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Moxifloxacin offers broad‑spectrum coverage against many Gram‑positive and Gram‑negative bacteria and has the convenience of once‑daily oral dosing. Compared with older fluoroquinolones, it has enhanced activity against atypical respiratory pathogens, but clinicians must consider resistance patterns and safety profiles when selecting therapy.

Moxibiot should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use it after the expiry date printed on the label.

Moxibiot is taken orally, usually with a full glass of water. It can be taken with or without food, but patients should avoid concurrent intake of antacids containing magnesium or aluminum, as these may reduce absorption.

Serious risks include tendon rupture or tendinitis, especially in older adults or those on corticosteroids; QT interval prolongation leading to cardiac arrhythmias; and severe allergic reactions such as anaphylaxis. Patients should seek immediate medical attention if they experience tendon pain, palpitations, or signs of a severe allergic response.

Moxibiot should be avoided in individuals with a known hypersensitivity to moxifloxacin or any fluoroquinolone, patients with a history of tendon disorders related to fluoroquinolone use, and those with significant cardiac arrhythmias or prolonged QT interval unless the benefits outweigh the risks.